Multiple Myeloma

Publication Date: April 1, 2019

Key Points

Key Points

In 2018, an estimated 30,770 new cases of multiple myeloma will be diagnosed in the United States, representing 1.8% of all new cancer cases.

The estimated number of deaths from multiple myeloma in 2018 is 12,770, representing 2.1% of all cancer deaths.

Despite significant advances and improvements in overall survival, multiple myeloma remains incurable and additional treatments are needed.

The median survival is just over 5 years and most patients receive 4 or more different lines of therapy throughout their disease course.

Treatment

...Treatme...

...Transplant Eligible...

...tients should be referred to a transplant cen...

...c age and renal function should no...

...optimal regimen and number of cycles remain un...

...ansplant should be offered to all trans...

...ociated with stem cell toxicity, such...

...ell collection (sufficient for more than one SCT...

...he level of minimal response required to p...

...elphalan is the recommended conditioning regime...

Tandem autologous SCT should not be...

...delayed SCT may be used as consolida...

Allogeneic transplant for multiple my...

...tion therapy is not routinely recommen...

...lidomide maintenance therapy should be rout...

...intolerant of or unable to receive...

For high-risk patients, maintenance therapy w...

...e is insufficient evidence to make modific...

The quality and depth of response should be...

...ial therapy for transplant eligible patients s...

...ded that depth of response be assesse...

...low dose CT scan has been shown to be super...


...Transplant Ineligible...

...ial treatment recommendations for patients with m...

...nt for patients with multiple myeloma w...

...ies for patients with multiple myeloma who are...

...ans/patients should balance the potential...

...ntinuous therapy should be offered over fixed...

...l of initial therapy for transplant ineligibl...

...epth of response for all patients should be assess...

...ufficient evidence to support change in type and...

...ation of therapy, one should define pa...

...mended that patients be monitored closely wi...


...Relapsed Disease...

...reatment for biochemically relapsed myeloma shou...

...cally relapsed patients with symptoms due...

...should be administered on first relapse, tho...

...lapsed multiple myeloma may be continu...

...should be taken into consideration when...

...stem cell transplantation, if not recei...

...of the patients should be assessed using the...

...t risk assessment at the time of re...

...sment of other risk factors such as re...

...nts with genetic high-risk disease...

...ts with renal insufficiency, drugs shou...

...nts with plasma cell leukemia or extra medulla...

...revised response criteria should be...

...measurable parameters need to be followed...

...s excluding marrow and imaging should b...

...ponse assessment should be performed afte...


...Algorithm On Management of Patients...


.... Drugs Used in the Management of Patients...


...stic Criteria for Active Multiple MyelomaHaving tr...


Table 3. Revised International Staging System...


...ble 4. Comparison of Select Risk Prediction M...


...IMWG Response CriteriaHaving trouble viewing...


...timated Cost of Drugs for Multiple MyelomaHa...